PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
GERM vs. XBI
Performance
Return for Risk
Dividends
Drawdowns
Volatility

GERM vs. XBI

Last updated Apr 2, 2026

Compare and contrast key facts about Amplify Treatments, Testing and Advancements ETF (GERM) and SPDR S&P Biotech ETF (XBI).

GERM and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GERM is a passively managed fund by Amplify that tracks the performance of the Prime Treatments, Testing and Advancements Index. It was launched on Jun 17, 2020. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. Both GERM and XBI are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

GERM vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

GERM vs. XBI - Yearly Performance Comparison

2026 (YTD)20252024
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF		5.43%35.89%-6.68%

Returns By Period

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
—
5Y*
—
10Y*
—

XBI

1D
0.64%
1M
1.58%
YTD
5.43%
6M
27.21%
1Y
65.07%
3Y*
19.25%
5Y*
-1.16%
10Y*
9.39%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Amplify Treatments, Testing and Advancements ETF

SPDR S&P Biotech ETF

Often compared with GERM:
GERM vs. SBIOGERM vs. EQRRGERM vs. GDOCGERM vs. MDEVGERM vs. ARKGGERM vs. BTECGERM vs. MNY.TO
Often compared with XBI:
XBI vs. IBBXBI vs. ARKGXBI vs. BBHXBI vs. VOOXBI vs. LABUXBI vs. BIBXBI vs. FBIOX

GERM vs. XBI - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is higher than XBI's 0.35% expense ratio.

GERM
Amplify Treatments, Testing and Advancements ETF
XBI
SPDR S&P Biotech ETF

Return for Risk

GERM vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
GERM
XBI
XBI Risk / Return Rank: 9393
Overall Rank
XBI Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
XBI Sortino Ratio Rank: 9494
Sortino Ratio Rank
XBI Omega Ratio Rank: 8989
Omega Ratio Rank
XBI Calmar Ratio Rank: 9696
Calmar Ratio Rank
XBI Martin Ratio Rank: 9595
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

GERM vs. XBI - Sharpe Ratio Comparison

Loading graphics...

Sharpe Ratios by Period

GERMXBIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

—

2.28

—

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

—

-0.04

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.29

—

Sharpe Ratio (All Time)

Calculated using the full available price history

—

0.36

—

Dividends

GERM vs. XBI - Dividend Comparison

GERM has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.34%.

TTM20252024202320222021202020192018201720162015
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF		0.34%0.37%0.15%0.02%0.00%0.04%0.20%0.00%0.28%0.24%0.26%0.61%

Drawdowns

GERM vs. XBI - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for GERM and XBI.

Loading graphics...

Drawdown Indicators

GERMXBIDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-63.89%

+63.89%

Max Drawdown (1Y)

Largest decline over 1 year

0.00%

-13.39%

+13.39%

Max Drawdown (5Y)

Largest decline over 5 years

—

-55.04%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-63.89%

—

Current Drawdown

Current decline from peak

0.00%

-25.70%

+25.70%

Average Drawdown

Average peak-to-trough decline

0.00%

-20.91%

+20.91%

Ulcer Index

Depth and duration of drawdowns from previous peaks

0.00%

3.65%

-3.65%

Volatility

GERM vs. XBI - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while SPDR S&P Biotech ETF (XBI) has a volatility of 11.31%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading graphics...

Volatility by Period

GERMXBIDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

11.31%

-11.31%

Volatility (6M)

Calculated over the trailing 6-month period

0.00%

19.25%

-19.25%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

28.95%

-28.95%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

32.23%

-32.23%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

32.15%

-32.15%